Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
U.K. and U.S. have signed a memorandum of understanding (MOU) that will see the U.K.’s Energy Africa initiative join forces with the U.S.'s Power Africa Initiative.
A landmark partnership between the UK and US will help millions of people across Africa get access to clean energy, UK International Development Minister Nick Hurd and Associate Administrator of USAID Eric Postel have announced.
The new partnership between the UK’s Energy Africa campaign and the US’s Power Africa initiative will leverage much-needed private investment, develop networks to share power across borders and harness geothermal resources to boost access to electricity across the continent.
http://www.newshour.com.bd/2015/12/08/britain-and-us-unite-to-power-up-africa/
Read more: http://www.pv-magazine.com/news/details/beitrag/cop21--africa-calls-for-55-billion-annual-energy-investment--15c-limit-to-global-temperature-rise_100022343/#ixzz3tnn8RbqD
DNRG will need to bring it come 2016. More & More big players coming on board so DNRG let's start with a fantastic NEW PR in January for some much needed upward movement.
I have seen DNRG's twitter and the odd "Go Cowboys" post. I think Michael Watkins (Michael Watkins is the President of DNRG) may do the posting on DNRG's twitter page the reason I say this is if you look at his Facebook page he has it everywhere. Michael Watkins may also have a past family member how was once on the football team maybe.
The odd posting could also be a result of a pumped up confidence on Watkins part. I believe he purchased more shares of DNRG in the amount of 8.5 million and DNRG could end up having one hell of a 2016-2017 that may be the reason why he posted that WHACKY "GO COWBOYS" stuff, overly excited?
Here is a link to Michael Watkins Facebook;
https://www.facebook.com/michaelwatkins0102?fref=ts
Powering Africa once again is heating up, Russia & The United Kingdom involvement, new article "Foreigners line up to power Africa" & Canada Pledging $150 Million of Climate Funds to African Renewable Energy Initiative.
Russia & UK;
http://beta.iol.co.za/business/news/foreigners-line-up-to-power-africa-1956606
Canada;
http://www.desmog.ca/2015/12/07/canada-pledges-150-million-climate-funds-african-renewable-energy-initiative
DNRG, bring on the big NEWS!!
New Article From Paris Conference "Africa is simply tired of being in the dark," Adesina said to a cheering crowd at the African Pavilion at the summit in Paris for the launch of the African Renewable Energy Initiative"
* Bank to invest $12 billion in energy within five years
* Only 32 percent in sub-Saharan Africa have electricity
* Project will work with others to boost investment
* Plan to skip carbon-intensive grow
http://www.reuters.com/article/2015/12/01/climatechange-summit-renewables-africa-idUSL8N13Q3C820151201#h0QSquWvRE6vmylG.97
The International Finance Corporation (IFC), a subsidiary of the World Bank Group and the Overseas Private Investment Corporation (OPIC) have announced financing agreement for the 53MW Cap Des Biches power plant.
http://www.esi-africa.com/ifc-funds-53mw-cap-des-biches-power-plant/
The project is being developed by US-based power project developer, Contour Global, which will design, construct and operation the heavy fuel, oil fired thermal power plant.
In a statement, the IFC will be "providing a cross currency swap" while OPIC will be provide $91 million for the project, which is expected to be complete by May 2016.
“Contour Global and OPIC have a strong history of partnership underpinned by results, and Cap des Biches is a milestone project both for OPIC and our support to President Obama’s Power Africa initiative,” OPIC’s President and CEO, Elizabeth Littlefield, said in the release.
“This is the first power sector transaction of any size for OPIC in Senegal and I look forward to its transformative effect on Senegal’s infrastructure and economic growth. It’s also an important step for OPIC’s energy presence in West Africa, an exciting region with tremendous development opportunity,” she added.
Need an article simliar to this on DNRG & the Rubicon,
"energy: Why solar is gaining prominence in Nigeria"
Read more at http://www.dailytrust.com.ng/news/business/clean-energy-why-solar-is-gaining-prominence-in-nigeria/121681.html#R3IGtzqSG42C1pvx.99
In the last five years, the adoption of solar energy technology and other renewable forms have gained a huge prominence in Nigeria.
The shift to renewable energy sources with solar leading the pack was heightened after the federal government privatised about 18 thermal generation and distribution power firms on November 1, 2013.
With the takeover of private firms, the federal ministry of power said it is shifting from a sole operator of power utilities to making more policies and developing a robust environment where solar technology and other renewable energy forms will thrive in Nigeria.
The former Minister of State, Power, Mohammed Wakil in 2014 committed the country to the United States initiative - Power Africa with a target of generating 10,000megawatts (mw) by 2020 mostly from renewable energy sources including solar, wind, coal and biomass.
The Ministry also began the development of a renewable energy document in 2014. The Federal Executive Council approved the completed National Renewable Energy and Energy Efficiency Policy (NREEEP) in April, 2015 to guide the teeming local and foreign investors.
Standing tall in the comity of nations, Nigeria and other developing countries attracted about $126bn investment in renewable energy in 2014 with solar topping the list. With more emphasis on climate change and the Paris Climate Change Summit, clean energy investment has been rising significantly in 55 countries, a global assessment this week said.
Nigeria rose up along the ladder as its renewable investment rose higher in 2014 than the year before.
The Bloomberg New Energy Finance (BNEF) reporting the Climatescope stated that the investment will become more significant with the country’s new policy guide.
Climatescope, the clean energy country competitiveness index, interactive report, and online tool supported by the UK government, US government, and the Inter-American Development Bank Group offers a compelling portrait of clean energy activity in 55 emerging markets in Africa, Asia and Latin America and the Caribbean The group includes major developing nations China, India, Pakistan, Brazil, Chile, Mexico, Kenya, Tanzania and South Africa, as well as dozens of others.
It said the new investment in renewables soared in 2014 in the 55 Climatescope countries assessed to hit a record annual high of $126bn up to $35.5bn, or 39 percent, from 2013 levels.
Solar is particularly competitive in emerging markets which often suffer from very high power prices from fossil generation while also enjoying very sunny conditions, the report said.
The Multilateral Investment Fund (MIF) of the Inter-American Development Bank Group (IDB), the UK Government Department for International Development (DFID), and the US Agency for International Development (USAID), under President Barack Obama’s “Power Africa” initiative, commissioned Bloomberg New Energy Finance (BNEF) to analyze and rank development prospects for solar, wind, small hydro, geothermal, biomass, and other zero-carbon emitting technologies (excluding large hydro).
The report provides potential investors with important information identifying countries with the greatest clean energy investment opportunities.
Nigeria signed many pacts with investors worth over N40billion mostly in > solar energy technology between 2014 and November 2015.
Chief of these investments steps is that of Osun state and the French firm, Vergnet Group in April 2014 which said they are putting in N6.1billion to build a 13mw solar power plant. The project to be sited in Osogbo was take off July 2014 and would last for 14 months.
Vergnet is also constructing the N5billion 10mw wind farm in Katsina which
would be the first of its kind in Nigeria.
Earlier in January 2014, the federal government flagged off solar power in three village, Durumi, Shape and Waru in the Federal Capital Territory under the Operation Light-up Rural Nigeria (OLRN).
In Durumi, over 1,000 households benefits from the energy source. The former Minister of Power, Prof. Chinedu Nebo said it was a pilot project and was meant to attract more of such across the 36 states.
In September, United States consortium, Global Business Resources, under the Power Africa said they would spend N17billion to provide two units of 50mw solar power plants in Kumbotso-Kano and Karu- Abuja towns.
The investment trend continued in 2015 when in February, the ministry signed another pact with a Nigerian-led Korean firm for 1,000mw solar plant to be sited in Kogi State. The firm said it secured a 2,700 hectares parcel of land from the state government to site the solar farm.
Ezetech, a Nigerian firm and two Chinese companies entered another pact in March for 1mw solar plants in clusters across the country. The Managing Director, Ezekiel Adeyemi said it has a proto-type 7.5kW solar-powered farm settlements in Ondo and 10kW in Ijebu Ode, assuring that the Company will showcase its expertise with world class technology.
Recently in November, a pact was signed for 50mw solar power in Machok-Kaduna state.
Beside the massive investment plans, the federal government is promoting the manufacturing of solar panels in Nigeria. This is expected to cut imports and make it affordable for household use in the Nigerian market.
The first solar panel manufacturing plant located in Karshi, Abuja would need $96million which is about N15.6billion to double its capacity from its estimated 7.5mw annual output, an official said.
The Executive Vice Chairman of the National Agency for Science and Engineering Infrastructure (NASENI) Solar Panel Manufacturing Plant, Engr. Mohammed Sani Haruna disclosed this early this yea.
The Managing Director Mr James Ocheje said “From the period of incorporation in September 2011, the plant has produced more than 2800 pieces of solar panels of different power ratings including 175 watts to 200watts capacity.”
At the recent Nigeria Alternative Energy Expo 2015, renewable energy experts said the use of solar energy is gaining more recognition but inventors would have to improve the technology for maximum energy conservation.
In his urge, former coordinator of government’s Operation Light-up, Dr. Albert Okorogu said, “Let us think about the real challenge of solar technology - how do we power systems at night where there is no sun, and during rainy and cloudy days?”
He said he alongside critical inventors are working on an invention that could surmount these while defeating the challenge of getting expand land to site an effective solar plant through miniaturization with long lasting Tesla batteries.
Read more at http://www.dailytrust.com.ng/news/business/clean-energy-why-solar-is-gaining-prominence-in-nigeria/121681.html#8DR6WtSvwsgmqE3X.99
Once Dominovas has a news piece similar to this Guardian piece picturing the Rubicon in area in Sub-Saharan field we should begin to see GREAT MOVEMENT with price.
http://www.theguardian.com/environment/2015/nov/23/how-africas-fastest-solar-power-project-is-lighting-up-rwanda
How Africa's fastest solar power project is lighting up Rwanda
East African plant is completed in less than a year – creating jobs and setting the country on the path to providing half its population with electricity by 2017
“Arise, shine for your light has come,” reads a sign at the entrance to the first major solar power farm in east Africa.
The 8.5 megawatt (MW) power plant in Rwanda is designed so that, from a bird’s-eye view, it resembles the shape of the African continent. “Right now we’re in Somalia,” jokes Twaha Twagirimana, the plant supervisor, during a walkabout of the 17-hectare site.
The plant is also evidence, not only of renewable energy’s increasing affordability, but how nimble it can be. The $23.7m (£15.6m) solar field went from contract signing to construction to connection in just a year, defying sceptics of Africa’s ability to realise projects fast.
The setting is magnificent amid Rwanda’s famed green hills, within view of Lake Mugesera, 60km east of the capital, Kigali. Some 28,360 solar panels sit in neat rows above wild grass where inhabitants include puff adders. Tony Blair and Bono have recently taken the tour.
From dawn till dusk the computer-controlled photovoltaic panels, each 1.9 sq metres, tilt to track the sun from east to west, improving efficiency by 20% compared to stationary panels. The panels are from China while the inverters and transformers are from Germany.
The plant’s construction has created 350 local jobs and increased Rwanda’s generation capacity by 6%, powering more than 15,000 homes. All this is crucial in an economy that, 21 years after the genocide, is expanding fast and aims to give half its population access to electricity by 2017.
Twagirimana, one of five full-time staff on-site, said: “The Rwandan government is in desperate need of energy. In 2013 they only had 110 megawatts. They wanted solar to increase capacity.”
The government agreed to a joint bid by Gigawatt Global, Norfund and Scatec Solar, backed by Barack Obama’s Power Africa initiative. Construction began in February 2014 and was finished by July. “It’s the fastest project in Africa.”
Its first year produced an estimated 15 million kilowatt hours, sending power to a substation 9km away, which has prompted mixed views in local communities. Twagirimana, 32, explained: “The neighbours say they want energy direct from here because they think it would be cheaper. It’s not true. We sell to the utility. Even our building gets power from the grid.”
The solar field is linked to a central server in Oslo and can be monitored remotely via the internet. Twagirimana believes it could be a template for the continent. “We have plenty of sun. Some are living in remote areas where there is no energy. Solar will be the way forward for African countries.”
The project is built on land owned by the Agahozo-Shalom Youth Village, where 512 young people are offered schooling and extracurricular activities. Facebook Twitter Pinterest
The project is built on land owned by the Agahozo-Shalom Youth Village, where 512 young people are offered schooling and extracurricular activities. Photograph: Cyril Ndegeya / AFP for the Guardian
The project is built on land owned by the Agahozo-Shalom Youth Village, whose mission is to care for Rwanda’s most vulnerable children orphaned before and after the genocide. This lease provides the biggest source of income to the six-year-old village, currently home to 512 young people who are offered schooling and extracurricular activities.
Jean-Claude Nkulikiyimfura, director of the village, said: “The project is probably the fastest: in less than a year it was up and going. It’s bringing a lot of visits from anyone interested in project development, and it brings some visibility for us. It’s something quite unique and we’re proud to be partners in it.”
Some of the village’s young people have received training at the solar site and one worked on the project. Other spin-offs have included a partnership to make solar panels for 250,000 homes. Nkulikiyimfura, 40, added: “Renewable energy is the way to go and we’re really proud to have it here. It shows what’s really possible when government works with the public and private sectors.”
One village member, 18-year-old Bella Kabatesi, who lost her parents to illness when she was four, has used solar power to design a night light at a memorial to the village’s late founder. “The big solar plant is going to help the people and the country because it’s cheaper than main electrical power,” she said.
Rwanda has been both criticised for trampling on human rights and praised for its unswerving focus on development and getting things done. Chaim Motzen, Gigawatt Global’s co-founder and managing director, and a solar industry pioneer in Israel, said: “Rwanda had 110 megawatts on the grid for a population of 12 million people; Israel has 13,000 megawatts for 8 million people. There was a desperate need for more energy.
This $24m project is the first utility-scale, grid-connected, commercial solar field in east Africa that has increased Rwanda’s generation capacity by 6%. Facebook Twitter Pinterest
This $24m project is the first utility-scale, grid-connected, commercial solar field in east Africa that has increased Rwanda’s generation capacity by 6%. Photograph: Sameer Halai/SunFunder/Gigawatt Global
“Rwanda has an excellent business environment – no corruption – and that played a role. I also think they were serious about wanting to move quickly. We had good partners on the ground. It’s now being used as a model: you can do energy deals quickly and get things done. It’s a catalyst for future projects in Rwanda and hopefully not just in Rwanda to inspire others to do what we’re doing.”
Solar energy is a key element in Africa’s future, Motzen believes. “Is it the only solution? No, because solar is intermittent. But will it be a major part of the solution? I believe it will.”
Yosef Abramowitz, president of Gigawatt Global, told a US government delegation and Bono at a site visit in August: “We have decoupled GDP growth from emissions growth. What you have heard is that we are 6% of a country’s generation capacity without adding any emissions. It is a false choice in Paris [the climate summit] and this is the proof test to be able to break that deadlock so that the world can go solar.”
How Africa Is Hacking Its Energy Crisis (great article on Africa, hope DNRG are a success across the board with their project & involvement)
Few videos in the link worth watching.
http://www.huffingtonpost.com/laura-ling/how-africa-is-hacking-its_b_8552150.html
At a small dispensary in a village just outside Dar es Salaam, Tanzania, I stared in disbelief as I watched health care provider, Recho Mengo, expertly balance a cell phone in her mouth so that she could free her hands to measure a pregnant woman's belly. The phone's flashlight was providing the only source of light in a facility that has no power. I couldn't help but think back to my own pregnancy less than two years prior; the situations were like night and day.
According to the World Health Organization, women in developing countries are dying every 90 seconds from complications during pregnancy or childbirth. As such, not having light can mean life or death. And when students struggle to read by kerosene lanterns in the dark of night, or young girls can't attend school because they must gather firewood and other sources of fuel for the household, the lack of energy can also mean holding back the dreams and advances of a new generation.
It's estimated that some 600 million people across sub-Saharan Africa do not have access to reliable energy. Ghanaian President John Mahama has been nicknamed Mr. Dumsor after the popular word for power outages. Lack of rain has forced the Tanzanian government to shut down hydropower plants, which generate 35% of the country's electricity. From Nigeria to Kenya and beyond, basic activities, such as studying and conducting business, often happen in the dark. Vital services - from delivering babies to caring for the sick - occur in dimly lit rooms.
The paradox is that Africa is home to the world's fastest growing middle classes and that technology has played a large part in this growth. Cell phone use in particular has exploded. In 2002, only 8% of Ghanaians said they owned a cell phone; today 83% use a mobile. Everything from basic communication to mobile banking is done using the cell phone. However, the infrastructure needed to simply charge these phones and to empower sub-Saharan Africa in general, just doesn't exist, leaving hundreds of millions of people in the dark.
2015-11-13-1447395313-1579989-hussein.jpg
Hussein Mwende, 18, studies by kerosene lamp because his home has no electricity.
Even in Dar es Salaam, Tanzania's largest city, it's hard to escape the crippling impact of blackouts. At Nelwa's Gelato Shop, I met owner Mercy Kitomari, who dreams of growing her business to include solar-powered gelato stands run by women entrepreneurs. But for now, Mercy struggles with the costs of keeping her product frozen. Rolling blackouts mean that Mercy must pay for an expensive generator to keep the power going. During my visit, the shop was in the midst of a power outage. The buzz and whirr of the generator permeated the air.
Whether by using flashlights on cell phones, generators, or solar powered charging stations, people are making it work despite the lack of power. But they shouldn't have to hack the energy crisis by finding creative work-arounds.
2015-11-13-1447395127-5081522-12_ChargingStation.jpg
A cell phone charging station in Dar es Salaam, Tanzania.
The UN's new Global Goals have made a commitment to provide universal energy access in Africa by 2030. Meeting these goals would undoubtedly transform the entire continent. But a key part of this roadmap is in providing clean energy.
During his address at the Power Africa initiative in July, President Barack Obama spoke about the opportunities African countries have to leapfrog over dependency on dirty forms of energy such as fossil fuels, and jump straight to embracing renewable energy. Businesses seem to agree. In October, Google announced its investment in a green energy wind project in Kenya, which would be the continent's biggest wind farm.
It's no surprise that the developed world uses vastly more than its share of resources. If the developing world consumed energy in the same way, it would be a global catastrophe. But with greater investment in alternative energy innovation, strong political will within Africa and outside its borders, and an end to endemic corruption, Africa could become a leader in sustainability, lighting the way for all of us.
2015-11-13-1447439161-2428465-MovieTheaterMkuranga.jpg
Movie theaters like these are in villages across Tanzania, since most homes do not have electricity. Besides paying to watch movies or sports games, residents can also pay to play video games at this theater in Mkuranga, Tanzania.
GM to Build Hydrogen Fuel Cell Truck for Army
(I hope DNRG looks into getting involved in a deal similar to this one with GM & the Army)
http://www.industryweek.com/emerging-technologies/gm-build-hydrogen-fuel-cell-truck-army
NEW YORK—General Motors said Thursday it will build a hydrogen fuel cell version of its Colorado pickup for the U.S. Army, giving soldiers a quiet and fuel-efficient reconnaissance vehicle for tough combat environments.
GM said the modified Colorado, a mid-sized pickup, would put its fuel cell technology to test under "the extremes of daily military use."
It signed a multi-year contract at the end of September with the army's Tank Automotive Research, Development and Engineering Center (Tardec) to develop and test the truck.
Tardec operates a fuel cell research facility close to GM's own fuel cell center near Detroit.
"The potential capabilities hydrogen fuel cell vehicles can bring to the warfighter are extraordinary, and our engineers and scientists are excited about the opportunity to exercise the limits of this demonstrator," said Tardec Director Paul Rogers.
The advantages for soldiers in the field of fuel-cell-powered electric engines are more than just the cheapness and unlimited supply of the fuel involved, hydrogen.
The engines run extremely quietly, and are also available to generate electricity for other field needs.
Moreover, the vehicles can offer a high amount of torque at low gear levels, which is important in rugged terrain and in carrying or pulling heavy cargos.
"FCVs are very quiet vehicles, on which scouts, special operators and other specialties place a premium," Rogers said.
"What's more, fuel cells generate water as a by-product, something extremely valuable in austere environments."
"It's environmentally friendly," said GM spokesman Dean Flores.
"The only emission is water. Beyond that, fuel cell vehicles can be used essentially as a portable generator. It can power hospitals" for example, he said.
GM has already been testing fuel cell engines in more than 119 Chevrolet Equinox sport utility vehicles for eight years, some of them used by the military.
In July, the company said they had, as a group, run over 3 million miles (5 million km) through every kind of weather, "proving that fuel cells can meet the demands of real-world drivers."
The U.S. automaker has also been working since 2013 with Japan's Honda to co-develop the next generation of fuel cell and hydrogen storage systems, with a target of 2020 for commercializing the technology.
The challenge to popularizing the technology includes a still-high vehicle cost, and the lack of infrastructure for distributing and replenishing the hydrogen fuel.
Copyright Agence France-Presse, 2015
PRINT
REPRINTS
FAVORITE
VERY TRUE. Here is two links with Jim Cramer speaking on Exactly how he manipulates the market. If DNRG does get up-listed next year to the Nasdaq you can bet DNRG will be "talked up" which could could lead to folks like Cramer looking to have DNRG come right back down cause Hedge Funds are shorting the stock.
(start watching at the 8 min. mark where Stewart nails Cramer in a lie)
http://walrusvideo.com/jon-stewart-vs-jim-cramer-march-12-2009/
(Cramer Manipulation)
https://www.youtube.com/watch?v=S2nX3FdRyR0
Just Start Watching At The 21min Mark. This Could Be Why The "SEC" Is SO...
Great Article On Everyone's Best Friend Adam Feuerstein! Must Read
Northwest Biotherapeutics stock woes highlight the harm of short sales
By Steven Pearlstein Columnist September 27, 2014 (Published over a year ago)
The past couple of weeks should have been heady ones for Bethesda-based Northwest Biotherapeutics.
The small biotech firm, with an innovative new vaccine treatment for brain, prostate and other cancers, had just received an initial green light from British regulators to offer its drug to doctors and patients even before its definitive Phase III trial is completed in the United States. The approval was the first under a new program designed to speed the process of getting promising treatments to market, and it follows a similar decision by Germany in March. Both European regulators cited independent analyses of results from earlier brain cancer trials showing that Northwest Bio’s immune therapy doubled the average of 17 months of extra life now provided by the standard treatment of chemotherapy and radiation.
Steven Pearlstein is a business and economics columnist who writes about local, national and international topics. View Archive
RSS
But as it happens, Northwest Bio’s stock, after a brief upward spike, ended the week down 11 percent below where it was the day before the news from Britain crossed the ticker. And therein lies an eye-opening tale of how hedge funds and their Wall Street allies stifle innovation and damage the economy in their relentless pursuit of short-term trading profits.
I’m talking, of course, about the “shorts” — investors who actively bet against companies by borrowing shares of their stock and selling them in the hope that the price will go down and they can buy them back at a lower price before returning the shares to their rightful owner. In theory, short-selling enhances the efficiency of markets by bringing in fresh information and capital. In reality, it has contributed to turning financial markets into a giant casino which is easily rigged for the benefit of insiders.
Biotech stocks are particularly vulnerable to manipulation by the shorts. They tend to be small, with low share prices and relatively few shares actively traded. And because of the high risk involved — relatively few biotech companies ever succeed — share prices tend to be volatile, easily moved by rumors and news of regulatory action.
These characteristics make it easy for a handful of hedge funds to anonymously drive down the price by selling borrowed shares into the market at the same time, creating a self-fulfilling momentum that scares off other investors. Even when they can’t get ahold of enough borrowed shares, they might sell the shares anyway and simply fail to deliver them three days later when they are due. That’s known as a “naked” short, and it’s illegal.
The shorts’ tactics, however, extend well beyond the trading room. As the nonprofit advocacy group Citizens for Responsibility and Ethics in Washington (CREW) lays out in a recent white paper, shorts are active in anonymously feeding false and misleading information about their target companies to friendly analysts and bloggers while using social media to attack the intelligence and motives of those who view the company favorably. They enlist plaintiffs law firms to issue press releases soliciting shareholders to sue the target companies for securities fraud. And they pepper regulators with threatening letters and fillings demanding that they investigate their targets or deny them product approvals.
Such tactics make it difficult and expensive for biotech firms to raise the large amounts of capital they need to conduct drug trials and build production facilities. They were all used in recent years to cripple Dendreon, another company that is a pioneer in the use of immune therapy for cancer treatment, which was so weakened by the shorts that it has failed to recover even after receiving its much-delayed FDA approval. And now they are after Northwest Bio.
As you can see from the accompanying chart, anytime the price of the company’s shares began to rise this year, it was hit with another wave of short sales that drove the price back down. By the end of last week, the total number of borrowed shares was reported to be about 8.5 million, or about 30 percent of the shares not held by company executives or entities they control. That level of short interest is unusual. It’s also suspicious — so much so that at one point this summer, shareholders could earn a 34 percent return by lending their stock to the shorts just for one month. Based on filings by brokerage firms, Northwest Bio estimates that, in addition to the 8.5 million reported short shares, there are as many as 4 million short “phantom” shares created by the “naked” transactions.
In late July, CREW’s executive director, Melanie Sloan, asked the Securities and Exchange Commission to investigate market manipulation of Northwest Bio’s stock. (Sloan told me her organization has never been contacted by the company and has no connection to its executives, investors or directors.)
In her letter, Sloan called particular attention to Adam Feuerstein, a biotech reporter whose relentlessly negative blog posts for thestreet.com this year have not only been filled with exaggeration, mischaracterization and half-truths, but curiously have also coincided with the spikes in short trading.
On March 11, for example, the day that German regulators announced their approval and Northwest Bio’s stock broke through $10, Feuerstein was quick to weigh in with a story that the company had withheld the news for two weeks to use it to divert attention from the fact that it had failed to deliver an interim report on the results of its Phase III trial back in the United States. As the chairman of the independent committee overseeing the trial later pointed out, there was no interim study and, by protocol, the company would have been prevented from seeing it even if there were one. As for that delay in getting out the good news, the company’s perfectly reasonable explanation was that it needed time to have the German notification translated into English and checked by the Germans.
The next month, on April 3, the headline on Feuerstein’s post was that Northwest Bio acknowledged that the FDA might throw out results of its Phase III study. It sounds pretty ominous. But all that really happened was that the company, in its annual report filed with the SEC, included that possibility in the long list of risks that investors should take into consideration, just as any company in the midst of a Phase III trial would have to do.
Or consider Feuerstein’s posts in May and June concerning a presentation by Northwest Bio’s chief executive, Linda Powers, at the big annual cancer research conference, in which she described how one patient had responded to the company’s therapy.
In both columns, Feuerstein expressed outrage that a drug company would exploit the suffering of patients for commercial gain (imagine that!) by selectively releasing results from a Phase I/II trial. He quoted Dr. Aman Buzdar, the head of clinical research at MD Anderson Cancer Center, the lead hospital for the Northwest Bios trial, criticizing the company for taking the “unusual and inappropriate” step of releasing such information. If Buzdar had first checked with his colleagues, however, he would have found that two of them had recently appeared in a National Geographic documentary focused on just such interim results from a pancreatic cancer patient. And, as CREW noted in its letter to the SEC, Buzdar himself made positive comments at a 1999 conference about a breast cancer drug he was testing that was still in clinical trials.
Then last week Feuerstein declared that the approval by London was really a “non-news event” because only one other company had applied for a similar approval since the program was launched in April. It was all just a smokescreen, he explained, to divert attention from the unfavorable terms on which Northwest Bio had recently raised another $27 million from investors in a hostile funding environment — a hostile funding environment, we should note, that Feuerstein himself had helped to create.
Feuerstein declined to speak to me last week, but his editor said she was sticking by her “dynamic” reporter. When I asked whether Feuerstein had been in contact with the shorts, she would only say that he was in touch with a wide range of investors. Using thestreet.com’s journalistic standards, the headline on that might be: “Biotech reporter concedes he may be exchanging information with shorts.”
I have no idea whether Northwest Bio’s immunizations work or whether it will become the billion dollar company that Powers says it could be. What I do know is that given the choice between allowing innovative companies to develop promising products that could save thousands of lives, or allowing Wall Street wise guys to use sleazy tactics to manipulate share prices for short-term profit, I’m siding with the companies. Maybe it’s time for the Justice Department and the Securities and Exchange Commission to be siding with them as well.
SEC's White Says Short Selling Getting Her ‘Intense Attention’ Nov.10 2015 @11:21am
http://www.bloomberg.com/news/articles/2015-11-10/sec-s-white-says-short-selling-getting-her-intense-attention-
M. Angela Cenci Nilsson, MD, PhD & Christopher U. Missling, PhD, MBA
Both Dr.'are listed on the MJF grant for 2015 under researchers for 2-73 Anavex drug. I haven't seen M. Angela Cenci Nilsson's name before this MJF site. Is she new to the company or did I miss this somewhere in my DD or does she work for the MJF Foundation?
Here is a link to the Michael J. Fox Grant & Anavex Grant where Dr. Nilsson is listed as a researcher?
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1450
https://www.michaeljfox.org/foundation/researchers.php?id=611
From Your Friend Jim Cramer;
"When I was short at my hedge fund and I was positioned short meaning I needed a stock DOWN I would uh create a level of activity before hand that could drive the futures. It doesn't take much money, similarly or if I was long and I wanted to make things a little bit rosy I would go in and take a bunch of stocks and make sure they were higher and maybe commit $5 million in capital to do it and I could affect it. What you're seeing now is maybe, its a bigger market so probably need $10 million in capital to knock the stuff down. But Its a fun game, and its a lucrative game. You could move it up and fade it that often creates a very negative feel. So lets say you take a long term view at your day and you say listen I'm gonna boost the futures and then when the real sellers come in, the real market comes in they are going to knock it down and create a negative view and thats a strategy very worth doing when you value on a day to day bases. I would encourage anyone in the hedge fund to do it cause it LEGAL and its a quick way to make money and very satisfying. By the way no one else would ever admit that but I don't care and I'm not going to say that on TV"
Sounds too familiar, don't you think??
Cramer quote "whats important when you're in that hedge fund mode is to not do anything remotely truthful, cause the truth is so against your view than its important to create a new truth to develop a fiction"
OPIC achieves $1.5billion spend in the sub-Saharan Africa energy sector
http://www.esi-africa.com/opic-achieves-1-5bn-spend-in-the-sub-saharan-africa-energy-sector/
AVXL patent approved date confirmed with link
Thanks to Brenda-brader for this site
portal.uspto.gov/pair/PublicPair
1. click application scroll down enter 14/205,637 then hit search
2. on top hit Image file wrapper
3. go to document description click the 10-21-2015 issue noitification. It will show patent issue dte is 11-10-2015. I hope AVXL will go up tomorrow because of this patent approval
If this has been posted already I'll delete.
walrusvideo.com/jon-stewart-vs-jim-cramer-march-12-2009/
Watch starting at 8mins. Exactly what is going on with AVXL!!
What is the Anavex warrant issue? When would this likely come into play for anavex???
1st CTAD twitter post are up from Saturday morning
https://twitter.com/IMI_EPAD
twitter feeds who are at the CTAD Conference:
https://twitter.com/Helen_Rice
https://twitter.com/AD_PREVENT
https://twitter.com/JeanGeorgesAE
https://twitter.com/IMI_EPAD
THIS IS SOME SERIOUS DD ON AVXL...credit goes to wolfwayne on ihub
WolfWayne Member Level Sunday, 08/09/15 06:36:58 PM
Re: None
Post # of 15249
DD regarding allegations questioning the credibility of Steve Macfarlane, Anavex media coverage, and P300 trends.
Allegation # 1 from cloeburner on reddit: "Look up Prana biotech; they had an Alzheimer's study led by the same researcher [Steve] "McFarlane" (sic). They produced similar results in phase two and then had the exact same Alzheimer's patient [Kelvin Lawler] serve as a miraculous example of their medication's efficacy. They rose to ten dollars or so then crashed precipitously.
Analysis of Allegation #1: I took cloeburner’s advice here and investigated the Prana, Macfarlane, and Lawler connection to determine the validity of this allegation. I have not spoken to cloeburner to determine the depth of his/her research; however, in attempting to follow this lead, I believe cloeburner’s due diligence here was only cursory. I have logged many hours researching this allegation and have determined there is indeed some truth to these allegations; however, the truth – as far as I can tell – is much more complex, and does not call into question the integrity of Macfarlane or Lawler. Moreover, the Macfarlane and Lawler connection in no way calls into question the integrity of Christopher Missling or Anavex. So what happened?
First, allow me to outline some background information that may be useful to investors who are not intimately familiar with Macfarlane. Macfarlane is the lead investigator for the ongoing Phase II A – PART A, Anavex clinical trial. Macfarlane was also the lead investigator for the Prana Phase II Imagine Trial, which was also tested for Alzheimer’s indication. Macfarlane is a central figure in Alzheimer’s clinical trials in Australia and Australia is among the worldwide leaders in Alzheimer’s clinical trials. Macfarlane is well respected throughout the world for his research and expertise in Alzheimer’s clinical trials.
On November 15, 2013, Today Tonight, a low-caliber Australian news agency, released a video titled “Breakthrough Alzheimer’s Drug”, which included an interview with Macfarlane, Lawler, and Lawler’s wife. I have scoured the websites and Facebook pages of Today Tonight, 7 Network Australia (the parent company), as well as Yahoo News Australia (the syndication servers) to no avail. I have also scoured forums of HotCopper, Delphi Forums, Yahoo Message Boards, Investor HUB, Reddit, StockTwits, Twitter, Seeking Alpha, etc. Following study of the social media forums mentioned above, I located several links to the video, which were without exception redirected to the Yahoo News Australia homepage or failed to load. I also found a few links to a private YouTube video that requires permission to view but does not enable users to request permission in the first place!
You can attempt to access the video via YouTube here https://www.youtube.com/watch?v=rvCE8CujeV0.
You can attempt to access the video via Yahoo News Australia here: http://au.news.yahoo.com/today-tonight/health/article/-/19826663/breakthrough-alzheimers-drug/
Despite my failures in accessing the video, I have learned a great deal about Today Tonight, Macfarlane, and Lawler.
Here are a few snippets of social media comments regarding the credibility of the video.
From Handel on Delphi Forums: “It seems to me that Today Tonight has…conflated two different stories, which would not be surprising considering their normal journalistic standards”.
From What A Gas on HotCopper: “If you go through the plethora of posts both here and on Yahoo MB, I think you will find that this rather pathetic piece of journalism spliced segments relating to two trials”.
From dontaskme on HotCopper: “Atrocious journalism now seems confirmed. The professor [Macfarlane] should take action for being misrepresented”.
From LostOut on HotCopper: “[Today Tonight] got hold of an [Imagine] trial participant showing good results and wanted to do a miracle cure story, but no one from the trial of Prana would talk to them. [Therefore], they set up the poor professor [Macfarlane] asked him about another trial completely, edited his responses carefully, and then conflated two trials, which explains why he was talking about antibodies. An example of ‘don’t let the facts stand in the way of a good story’ journalism, but what do you expect from [Today Tonight]? Nevertheless… it was built around a grain of truth”.
Prana took issue with the video as well and subsequently issued a press release denouncing the media coverage, denying any participation or awareness of the coverage, as the Prana study was not yet unblinded. You can view the press release here: http://www.marketwired.com/press-release/prana-responds-to-media-segment-under-asx-guidance-note-8-nasdaq-pran-1853018.htm.
Shortly after, it appears the video was removed from Today Tonight as well as YouTube. I have emailed Today Tonight asking for access to the original video but have not received and answer and likely will not, as it is possible that a gag order exists. The poor journalism of Today Tonight led to a spike in Prana share prices, that later crashed when Prana failed to demonstrate statistically significant results in their Imagine Trial for Alzheimer's. Certainly Macfarlane, Prana, and Prana shareholders were none too happy with Today Tonight. Today Tonight’ legal team probably thought best to remove the video; however, for whatever reason, a summarized article of at least a portion of the video remains available on the Today Tonight website. The article can be viewed here: http://www.7perth.com.au/view/today-tonight-articles/today-tonight-alzheimers-trial
The summarized article includes quotes from Macfarlane that are derived from his published works, although the article does not state as such. It is also possible that Macfarlane quoted himself, knowing these statements were already public knowledge. Nonetheless, Macfarlane’s discussion of Lawler as the poster boy for clinical trials is not derived from his published works, and without the original video it is impossible to determine whether or not Macfarlane actually said this or not. Nonetheless, a feel-good statement as such is not a violation of double-blind protocol. In fact, in double-blind protocol, Macfarlane would not be aware whether Lawler was taking a placebo or the Prana drug in question.
Allegation # 1 Conclusions: I have no reason to question the integrity of Macfarlane or Missling’s decision to request Macfarlane to serve as the lead investigator. However, I do have significant doubts about the journalist competency and integrity of Today Tonight and the parent company 7 Network Australia.
Allegation # 2 from "watsonofoz" on yahoo: “The video related to the [Anavex 2-73] Phase 2a [Part A] PR may be, in part, a hoax. Claims on this board that an AD patient, Lawler, said, "It's like being in the dark, and then someone switched the light on" are not true. Lawler's wife finished…Lawler's sentence because he could not remember the last part. Was this a carefully rehearsed line with his wife that went awry when Lawler could not remember the ending?”
Allegation # 2 Analysis: First, it seems implicit from analysis of Allegation # 1 that Lawler is a local resident who became familiar with both Caulfield Hospital and Macfarlane. Accordingly, Lawler seems to have completed the Imagine extension trial and later sought to enroll in the Phase II A, Part A Anavex 2-73 clinical trial. Logic dictates this does not indicate a conspiracy but rather proves Lawler is not yet cured. This has not prevented allegations that the Anavex 2-73 video featuring Lawler was a hoax and that Macfarlane and Lawler are somehow complicit in fraud. Piggybacking this alleged conspiracy, some have alleged that Missling is also complicit and specifically selected Macfarlane because of his willingness to participate in another fraud. If the claims about Lawler and Macfarlane are baseless, so too are the claims about Missling.
Admittedly, I did not attempt to contact watsonofoz because his/her claims seem to be speculative and opinionated. Nonetheless, if I understand the claims of watsonofoz, his assertion is operating under the assumption that Lawler’s wife is not loving, protective, and familiar with finishing the sentences of her husband, and Alzheimer’s sufferer. This happens with great frequency with sufferers and is likely to occur on camera when the wife of a sufferer is trying to protect the dignity of her husband, at least in my opinion. Moreover, it seems as if Lawler is indeed in the process of trying to recall and sound out the word light. Again, “losing” words in conversation is indicative of the disease. Regardless, Lawler struggles do not indicate failure in Anavex 2-73 after merely 36 days of treatment. Insinuating a conspiracy here lacks basis and is merely speculation.
Regarding the producer of the video watsonofoz is questioning here, you might be surprised to learn that 7 Network Australia is also responsible for the production. As such, you will see a poorly edited transition into the discussion of Solanezumab, followed by a few words of Jack Sach, concluding with an abrupt return to Lawler, and his wife, which further exacerbates the point that the producers of this film exercised editorial liberties to create a fluid narrative. To the nonprofessional, it seems as if Jack Sach, Solanezumab, Kevin Lawler, Steve Macfarlane, and Anavex 2-73 are all participating in one study. We, here on this forum, know this not to be true; however, perception is reality to most and we cannot deny that aspect of human confusion. Not a critical piece of information here; however, given the lack of availability of the video discussed in Allegation #1, this video provides insight into the confusing splicing practices of 7 Network Australia. You can watch the video here: https://au.news.yahoo.com/video/watch/29015798/new-pills-offer-hope-for-alzheimers-sufferers/#page1
Fortunately, for Anavex and Anavex shareholders, MSN Australia provided coverage of another Phase II A, Part A, Anavex 2-73 clinical trial participant in Frank Merkli. This video makes the 7 Network Australia issues in the Anavex 2-73 coverage a mute point, at least in my opinion. You can watch the video here: http://www.msn.com/en-au/health/other/ground-breaking-trials-show-new-alzheimer%E2%80%99s-drug-to-be-four-times-more-effective/vi-AAdmZ8F?ocid=st
Allegation # 2 Conclusions: I have no reason to question the integrity of Lawler or his wife. Although the quality of journalism is again lacking in the 7 Network Australia video given the misleading splicing of two ongoing clinical trials, Anavex investors can easily omit the Solanezumab segment and focus on Lawler, his testimony, and the testimony of Macfarlane. Significantly, Macfarlane was free to discuss the results of the first patient data of Phase II A, Part A of the Anavex 2-73 clinical trial when this video was filmed, as Anavex had previously released the associated poster at AAIC 2015. In short, Lawler’s inclusion in this video is not indicative of fraud; rather, it is indicative that Alzheimer’s drugs can and do fail and that Lawler is still seeking experimental treatment. Can you blame him? Moreover, I still have no reason to question the integrity of Macfarlane or Missling’s decision to request Macfarlane to serve as the lead investigator. However, I do have significant doubts about the journalistic competency and integrity of Today Tonight and the parent company, 7 Network Australia.
The sole concern I have following analysis of Allegation # 2 is the wisdom in allowing Lawler to participate in the Phase II A, Part A of the Anavex 2-73 clinical trial given Lawler’s prior treatment in the Prana Imagine Trial. For better or worse, could the prior effects of the Prana Imagine Trial potentially prove an uncontrolled variable for Lawler’s treatment? At any rate, we might assume 31 out of 32 participants of the Phase II A, Part A of the Anavex 2-73 clinical trial were not involved in previous clinical trials. However, is this assumption wise? In other words, is there any way for us to know how many other participants previously participated in Alzheimer’s clinical trials? Admittedly, this concern hinges on the assumption the Lawler was either in the group within the Prana Imagine trial that received the drug and not the placebo and/or Lawler continued into the unblinded extension period. It is logical to me that Lawler would have moved forward into the extension period, given the claims of Lawler’s wife that the Prana treatment was indeed helping her husband, as evidenced in the original Today Tonight video/article, it is logical Lawler would have proceeded into the extension period.
We should ask Anavex IR about this, perhaps.
Allegation # 3 from superokgo on reddit: "I'm confused about why [Anavex] didn't release the MMSE cognitive test scores. They said they are in-line with the P300 values, but the P300 values do not mean much by themselves. The scores on the cognitive tests are what determine if it is actually working. [Moreover], there seems to be some controversy about whether the P300 even correlates with cognitive ability to begin with. I saw this post on yahoo (here) where the lead researcher addressed it, but it seemed like a non-answer to me. He just referenced an old study from 2002 and called it good. Weird."
Allegation # 3 Analysis: As demonstrated above, allegations have arisen that the results for the Phase II A, Part A first patient data for the Anavex 2-73 clinical trial are premature and the results are not statistically significant. As these allegations have surfaced elsewhere, namely via Adam Feuerstein, I did not attempt to contact superokgo for clarity in his question. More pointedly, it is clear that the first patient data was not statistically significant; however, the data was never intended to prove statistical significance. Upon review of the clinical trial design, it is clear to me that Phase II, Part A, never intended to demonstrate statistical significance in either MMSE or ADAS-COG changes. In fact, Phase II A, Part A was designed to capture a baseline for patients MMSE and ADAS-COG changes that would later juxtaposed in Part B. Per clinicaltrials.gov, the Primary Outcome measure of the trial is to “determine maximum tolerated dose of Anavex 2-73”. The Secondary Outcome measures include the following, which you can view here: https://clinicaltrials.gov/ct2/show/record/NCT02244541?term=anavex&rank=1.
• PK sampling- blood test results (PART A), first period (hours): 1, 48, 264; second period (hours): 1, 72, 264; extension period (PART B): Week 1, 12 and 26.
• MMSE Baseline, and during the extension period at Week 1, 12 and 26.
• ADCS-ADL: Baseline, and during the extension period at Week 1, 12 and 26.
• CBB Score and ISLT score at baseline, Day 1, 2, 6, 9, 12 of Period 1 and Day 1, 2, 6, 9, 12 of Period 2 and during the extension period at Week 12 and 26.
• EEG/ERP: Baseline, Day 1, 5, 11 of Period 1 and Day 1, 5, 11 of Period 2 and, Week 12 and 26 of the extension period.
• HAM-D Score: Baseline at Period 1.
• RM/HIS10: Baseline at period 1.
Significantly, you might have noticed the absence of ADAS-COG measurement in the trial design; however, you likely noticed the inclusion of the CBB. According to cogstate.com, recent research indicates CBB is more effective than ADAS-COG in determining cognitive measures. More importantly, cogstate.com asserts that CBB is “well placed to assist in the search for true disease modifying drugs as well as symptomatic treatments”. You can view the article discussing the study here: http://cogstate.com/two-new-alzheimers-disease-studies-show-sensitivity-cogstate-tests/
Within the framework of the Phase II A, Part A trial design, first patient data merely demonstrated a trend in cognitive improvement consistent with relationship between P300 and MMSE, and ADAS-COG changes, as demonstrated in a previous study of Aricept – which also served as the historical control. As such, the Anavex 2-73 trend is quite positive despite lacking statistical significance up until this point. We likely will not have statistical significance until after the Phase II A, Part B study. Regarding the validity of P300 correlation and cognitive improvement, it comforts me to know that Anavex is using the current standard of care P300 correlation as a milestone measurement! This is exactly the same sentiment of Macfarlane’s alleged email, as posted on Yahoo Message Boards
Also of significance is what Macfarlane has said up until this point regarding cognitive improvement. Upon review of the two news stories covering Anavex linked above, you will learn that participant caregivers noted improvements in function, behavior, alertness, and decreased need for prompting in activities of daily living. You will learn that preliminary brain scans show Anavex could be four times more effective than current standard of care medication, and that Anavex 2-73 saw 10 out of 12 patients improve four times as much at one month on their EEG reading than the current standard of care medication. Lastly, will learn that Macfarlane states that this is probably the most exciting thing he has been involved with in his entire life!
Allegation # 3 Conclusions: I am comfortable with the trial design, the data to date, as I understand statistically significant data as it relates to cognitive improvement will not be available until after the Phase II A, Part B portion of the study. Given the participant-initiated request to extend from 26 weeks to 52 weeks, I rest assured the patients are likely improving cognitively, and the full 52 weeks will allow quantifiable data to be collected that COULD demonstrate statistically significant improvement in MMSE and CBB, amongst other improved scores. Still, I understand the caution superokgo and others on IHUB, Yahoo Message Boards, and Seeking Alpha have voiced in an effort to temper our expectations in the near term, particularly as it relates to exponential PPS movement.
Moving Forward: At this time, I am holding 50,000 shares and intend to hold all 50,000 shares through Phase II A, Part B. For personal reasons, I have decided that I am going to use my remaining equity I acquired from selling 10,000 shares to bring my personal debt to $0, with the exception of my investment property mortgage. I understand the opportunity cost in doing this should AVXL skyrocket; however, I also understand the importance of mental tranquility when all debt is paid off, and any added fortune AVXL might bring my family is simply a blessing from God. With the remaining cash on hand, I intend to day trade AVXL in an effort to further my self-driven educational agenda. I remain fully confident in Anavex Life Sciences; however, I encourage you do to do your own DD and arrive at your own conclusions. Moreover, I can assure you a few hours of DD will bring you much more confidence in your investment than weeks of speculating and following others about PPS on social media.
Lastly, I encourage each of you to counter-argue any points or conclusions you may disagree with regarding what I have stated in this DD.
God bless you, your family, Anavex, and those affected by Alzheimer’s.
https://screen.yahoo.com/pills-offer-hope-alzheimers-sufferers-084935165.html
Lets not forget
CTAD CONFERENCE ON SAT 9:30am Axovant ///// 9:45am Anavex
At 9:30am Axovant is presenting RVT-101 (review of the preclinical & clinical results & status of the Development program.
At 9:45am ANAVEX (right after axovant present) New Exploratory Alzheimer's Drug Anavex 2-73: Assessment of Safety &Cognitive Performance in Phase 2a Study in mild-to-moderate Alzheimer's Patients
With the amount of education Anavex has on its team I don't see them getting "Late Breaking Communication" status to the CTAD Conference to underperform or come to the table with "bad news" especially with Axovant presenting right before them. If anything I believe Dr. Missling's team may steal the SHOW!!
Anavex Bonus:
Daniel Klamer, PhD
Senior Director of Business Development at Anavex Life Sciences Corp
Summary
Bringing science and business together, I drive promising strategies and initiatives with lasting results.
As a neuroscientist with a PhD in Pharmacology, my background includes years of clinical and pre-clinical research, development of preclinical hypotheses into proven concepts, and supervision of other scientists’ promising projects.
In the business world, I have led key projects from discovery to development, assessed and analyzed new opportunities for acquisition and partnering (often with limited resources), cofounded a startup, attracted and secured investments, and played a central role in deal execution.
With these combined experiences and skills, I:
- Translate ideas into viable commercialization
- Break problems apart and create effective solutions
- Effectively assess the risks and benefits of potential buyouts/mergers
- Identify promising opportunities for partnership
- Build collaborative relationships with clients and partners
- Create and present realistic, executable timelines and plans for strategic projects
- Align and engage teams to highest performance and productivity, and inspire them to achieve key goals
It is a privilege to apply my skills and expertise at Anavex and contribute to new and effective biopharmaceutical treatments for debilitating diseases.
https://www.linkedin.com/profile/view?id=AAEAAADTVioBc7qccNXn8K6uWaJkSLenM46EEas&authType=name&authToken=8QXA&trk=prof-sb-browse_map-name
HIRED 3 MONTHS AGO -- Daniel Klamer, PhD Senior Director of Business Development at Anavex Life Sciences Corp.
------------This doesn't read like a company that is setting up to come up short on Sat at the conference
Senior Director of Business Development
Anavex Life Sciences Corp.
------------------September 2015 – Present (3 months)
Lead the strategic sourcing and assessment of new market opportunities, acquisitions, and partnerships, and develop the business case (scientific and commercial) for key initiatives.
• Assess new, competitive, and potentially synergistic therapeutic compounds or devices.
• Lead detailed diligence on potential deals.
• Drive execution of new collaborations, licensing, and acquisitions.
• Advise senior executives on key strategic decisions.
------------Something tells me that Dr. Missling might be a very good chess player, how good we will soon find out -
Good, bad, or indifferent I like her. This is the true sprit of an investor, lean in with your face and you have to commend her spirit!!. We (ihub) need more of her on the board.
Same could be said about Dominovas, right ?
You're not alone "$DNRG is going ballistic this week... wait til what we see coming hits the PR wires"!!!!
Now lets see how close this prediction comes...
Once the 1st Rubicon is given a release date and photos of the shipment/installation of the Rubicon hit the internet this stock could stabilize at $0.25-0.40.
Then once Dominovas has revenue to report from the installation of the Rubicon & Powering Africa could see DNRG hit around $1.00. This is all likely to happen in or around the middle to end of 2016, so seeing DNRG at $1.00 might be 6-8 months down the road.
Dominovas Energy Corp. (OTCMKTS:DNRG, DNRG message board) tripled its market value two days ago, after announcing that it has received billions of dollars worth of funding for one of its projects. Unfortunately, the fact that a filing on the matter has not been made has cast a shadow of doubt on the whole affair, and as a result the ticker lost about half of its gains the very next day.
To a reasonable investor, this crash would look just as warranted as the jump that preceded it was baseless. The question of whether or not DNRG has really received the ridiculous amount of funding it claimed to have secured will probably make or break this ticker in the market sessions that follow.
If a report stating that DNRG is to receive more than $1.2 billion to work on its RUBICON™ SOFC systems does come out eventually, its investors will have a very real reason to celebrate.
If, however, it turns out that this is not the case, the light at the end of the tunnel will go out pretty quickly for its loyal supporters and many opportunistic traders alike - not only because DNRG will not get the money, but because its credibility will be ruined. Further, the SEC tends to take a very dim view of companies that spread misinformation of such caliber.
This is why investors need to be really careful with DNRG. Before it becomes clear what direction the ticker will take, any sort of investment in it will be a dangerous gamble that will most likely result in either spectacular success or devastating failure.
In light of DNRG's meager achievements to date, it should be obvious which outcome is more likely. With this in mind, let the buyer be ware.
Once the 1st Rubicon is given a release date and photos of the shipping or installation of the Rubicon hit the internet this stock could stabilize at $0.25-0.40.
Then once Dominovas has revenue to report from the installation of the Rubicon & Powering Africa then likely to see DNRG hit around $1.00. This is all likely to happen in or around the middle to end of 2016, so seeing DNRG at $1.00 might be 6-8 months down the road.
livestream.com/nasdaq/live Anavex name is now up on the screen!!
livestream.com/nasdaq/live
Anavex to Ring The Nasdaq Stock Market Closing Bell Oct 30 @ 4pm
http://www.nasdaq.com/press-release/anavex-life-sciences-corp-nasdaqavxl-to-ring-the-nasdaq-stock-market-closing-bell-20151029-01034
I looking forward to a great another great run!
There is a saying, "if there is someone smart enough to sell it, then there will be someone dumb enough to buy it"
I know that DNRG is on the usaid.gov list with large numbers attached with its name and the Africa project. But I have the ticker sign and Dominovas Energy Corp on google alerts along with Power Africa Initiative and NOTHING picked up yesterday or today not 1 google alert article associated with $1.2 BILLION or 1 article mentioning DOMINOVAS ENERGY & POWER AFRICA. Yet I have seen 4 articles in the last week on OPIC financing of $400 million with SOLORRESERVE. Google actually buys a 12.5% stake in Africa’s largest wind-power project by purchasing a stake held by Vestas, a Danish manufacturer and installer of wind turbines.
My concern is why has all the above commitments seen an article put out by a newswire but NOTHING with regards to an article on Dominovas & $1.2 BILLION commitment. Just why is this company treated like a red headed step child????
www.ippmedia.com/frontend/index.php?l=85539
http://www.prnewswire.com/news-releases/opic-partners-with-solarreserve-and-acwa-power-to-develop-landmark-south-african-solar-energy-facility-300162636.html
http://qz.com/530601
http://qz.com/530601/google-is-supporting-yet-another-huge-clean-energy-project-in-africa/
Dominovas made a staggering announcement yesterday, claiming to have secured $1.2 billion to fund the initial phase to manufacture, produce, and deploy of its RUBICON™ SOFC systems. The ticker promptly jumped 224.16% up in the air, on an amazing $2.5 million volume – but was that jump a bit premature?
Let's just say that DNRG has been known to make exaggerated claims on previous occasions. Yes - its announcement was lout and boastful, and yes – if it is true, it could mean that the company is headed for the top. But here's the thing – at this point in time there is no real proof that such an agreement actually exists.
Check the company's SEC profile. There's nothing in there about the much overhyped funding agreement. Why hasn't it been reported yet? Usually when such important matters are concerned, the filing accompanies the PR or vise versa.
The fact that the all-important proof of the company's claims to glory is missing should raise an immediate red flag in the minds of investors. After all, this could be a ruse – a clumsy plan to create insane levels of hype and push the ticker sky-high, so that the company's stock could become liquid, if only momentarily.
Since there is no filing at the present moment, it is impossible to be sure that this is not, in fact, the case. However, the fact that DNRG has performed various stock-related shenanigans over the years, and doesn't seem to have let go of that habit by now, should definitely be taken into account by investors. What do we mean?
In the first two quarters of 2015 alone, DNRG has issued notes for approximately $300 thousand worth of debt convertible into stock at a 50% discount. June and July 2015 have seen 35.6 MILLION new shares issued as a result of the conversion of $68 thousand worth of notes. That brought the shares outstanding at the time to a whooping 131 million. By mid August, that number had grown by almost 40 MILLION shares. The fact that DNRG's shares authorized were increased from 200 million to 700 million speaks loud enough in and of itself.
So let's do a quick recap the situation described so far. Dubious penny stock company with little to no achievements to date and a ton of toxic debt makes big announcement. The ticker skyrockets, in spite of the fact that the company's claims are unproven and, in light of its mediocrity to date, seem unrealistic.
At this point, it should be pretty obvious how this story's going to end.
Article from HotStocked.
USAID’s Development Credit Authority will provide $75 million in loan guarantees to fund the scale up of off-grid energy investments in sub-Saharan Africa
https://www.devex.com/news/off-grid-solar-power-is-gathering-steam-in-africa-what-s-next-87149
So what’s the problem?
It’s not growth. There is money out there from investors, especially for the frontrunners who have shown they can deliver returns, but what’s been lagging is working capital. For companies that rely on cash sales and are selling devices to retailers it’s a critical component to operating and growing business.
Companies have told Sturm they expect they could continue on the path they were on a year ago with 100 percent year-on-year growth if they had working capital.
IFC is working to help leverage additional financing, in part through its $10 million investment in ResponsAbility’s Energy Access working capital debt fund. The World Bank Group member would like to invest more in this area, according to Sturm, and is interested in working with local banks to create new types of financing to support customers who want to buy these products.
Government regulations can have a big impact on market growth. Countries that are not corrupt, have supportive business environments, don’t have a high kerosene subsidy, generally have low tariffs and import fees, and decent infrastructure will be the most appealing. Working with countries to change bad policies and encourage favorable ones will help future industry growth.
And while innovation may happen at a slower place, there’s plenty of room for more — particularly in products and appliances like low-watt televisions and fans that consumers are demanding.
Because as people gain access to electricity they tend to want to move up the energy access ladder pretty quickly. So making that affordable, and providing the finance and the business models to make it happen, will be important.
The same sentiment on the yahoo message board as well read below
"More deleting of vistor comments going on the Dominovas Facebook Page"
"I will say, good, bad, or indifferent they have chosen a unique way to deal with questions and concerns on their FB Page. I will say they did answer one concern and then deleted another by Phillip Demaggio and his comment was word for word "it would be great to get a PR on what the company has accomplished in Africa. I invested quite a lot of money and have been watching the stock drop everyday. I am down 50% (20K). Any idea when we can expect to hear new news"
I understand you (DNRG) may not like the comment with regards to the money lost to any new investors but hiding it only can lead to a mistrust with how you choose to do business and as you make your choices and build a history of choices it might look as if you are willing to hide and lie to us but it is your choice to do so. Only time will tell if you know what you are actually doing here or if you have bitten out off more than you can chew"
My own thoughts below:
Very interested in if DNRG will release PR this week. Seem to be a lot of forward movement in the news with Power Africa lately.
In the last week we have
OPIC & Solar Reserve a 15 million dollar commitment, OPIC and Nova-Lumos (Lumos) Solar, recognizing $400 million commitment of debt financing to support the development of the Redstone Concentrating Solar Power (CSP) project in Northern Cape, South Africa
Google has said it will invest up to Sh4 billion in a wind power project, expected to generate 310MW of clean energy, at Loiyangalani, Marsabit county. Along with Google acquiring a 12.5% stake in powering Africa by purchasing a stake held by Vestas.
The company will partner will investors including Overseas Private Investment Corporation, US government’s development finance institution and Vestas in the Lake Turkana Wind Power project.
Lastly from the past week UDOM solar project and Hecate Energy to produce 55 MW of electricity in six sub Saharan countries and are one of the USA’s leading developers of large scale renewable energy projects.
I have to say you did put words in my mouth a bit. I never in any of my posts called DNRG a scam, but it may have been a bit of Freudian slip on your part. If you have even 1 gram of doubt only means you're human and you don't then well that ain't human.